Clinical trial
Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis
NCT03587844 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 3, 2018
- Completion date
- July 31, 2027
- Enrollment
- 58 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.